Factor X-activating activity from Lewis lung carcinoma.
作者信息
Hilgard P, Whur P
出版信息
Br J Cancer. 1980 Apr;41(4):642-3. doi: 10.1038/bjc.1980.109.
Abstract
摘要
相似文献
1
Factor X-activating activity from Lewis lung carcinoma.
Br J Cancer. 1980 Apr;41(4):642-3. doi: 10.1038/bjc.1980.109.
2
Evidence that cells from experimental tumours can activate coagulation factor X.
Br J Cancer. 1979 Aug;40(2):228-33. doi: 10.1038/bjc.1979.170.
3
Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency.
Biochem Pharmacol. 1983 Jun 1;32(11):1689-91. doi: 10.1016/0006-2952(83)90110-7.
4
Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor.
Cancer Res. 1977 Jan;37(1):272-7.
5
Reduced procoagulant activity of Lewis lung carcinoma cells from mice treated with warfarin.
Eur J Cancer (1965). 1980 Dec;16(12):1641-2. doi: 10.1016/0014-2964(80)90041-9.
6
Interaction between heparin and adriamycin in mice bearing the Lewis lung carcinoma.
Biomedicine. 1981 Dec;34(3):124-8.
7
8
Blood amino acid compartmentation in mice bearing Lewis lung carcinoma.
Cancer Res. 1987 Nov 1;47(21):5644-6.
9
Cancer cell procoagulant: a novel vitamin K-dependent activity.
Thromb Res. 1981 Nov 1;24(3):263-6. doi: 10.1016/0049-3848(81)90097-9.
10
Fate of recirculating B16 melanoma metastatic variant cells in parabiotic syngeneic recipients.
J Natl Cancer Inst. 1977 Jun;58(6):1867-72. doi: 10.1093/jnci/58.6.1867.
引用本文的文献
1
Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems.
Int J Mol Sci. 2023 Nov 1;24(21):15855. doi: 10.3390/ijms242115855.
2
A factor X-activating cysteine protease from malignant tissue.
J Clin Invest. 1981 Jun;67(6):1665-71. doi: 10.1172/jci110203.
3
Role of plasma, platelets, and endothelial cells in tumor metastasis.
Cancer Metastasis Rev. 1984;3(2):99-114. doi: 10.1007/BF00047657.
4
Procoagulant activity of human tumours: existence of Xa and thrombin-like activities.
Br J Cancer. 1990 Jan;61(1):29-31. doi: 10.1038/bjc.1990.7.
5
Non-tissue factor procoagulants in cancer cells.
Cancer Metastasis Rev. 1992 Nov;11(3-4):267-82. doi: 10.1007/BF01307182.
本文引用的文献
1
Experimental vitamin K deficiency and spontaneous metastases.
Br J Cancer. 1977 Jun;35(6):891-2. doi: 10.1038/bjc.1977.135.
2
Evidence that cells from experimental tumours can activate coagulation factor X.
Br J Cancer. 1979 Aug;40(2):228-33. doi: 10.1038/bjc.1979.170.
3
Mechanisms of metastasis.
Biochim Biophys Acta. 1979 Feb 4;560(1):135-66. doi: 10.1016/0304-419x(79)90005-2.
4
Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.
Thromb Res. 1975 Feb;6(2):127-37. doi: 10.1016/0049-3848(75)90018-3.
5
Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts.
Cancer Res. 1978 Aug;38(8):2467-72.
6
Warfarin enantiomers, anticoagulation, and experimental tumour metastasis.
Lancet. 1978 Jan 21;1(8056):163-4. doi: 10.1016/s0140-6736(78)90472-5.
7
Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL).
Br J Cancer. 1977 Jan;35(1):78-86. doi: 10.1038/bjc.1977.6.
Zotero 插件